For Preventive Health
For Healthcare
For Research
Improve trial sensitivity
Capture functional change before behavioral scores reflect it. Reduce screen failures and improve endpoint sensitivity in clinical trials.
FOR RESEARCH
Objective cognitive measurement for clinical research
ViewMind captures objective cognitive data sensitive to early functional change and longitudinal monitoring.
Cognitive measurement built for scientific rigor
High-resolution brain health measurement for clinical studies and pharmaceutical research: ViewMind captures precise eye-movement responses during validated cognitive tasks, producing physiological and behavioral data sensitive enough to detect early functional change and reproducible enough to monitor subtle changes and for longitudinal study designs.
Researcher reviewing study data on a monitor
Use cases across research designs
Pharmaceutical companiesBiotech companiesAcademic research institutionsCROsClinical investigators
Enable precise patient stratification
Differentiate cognitive profiles across disease stages, treatment arms, and risk categories with domain-specific, reproducible data.
Scale across sites and populations
A 10–15 minute, non-invasive, culture- and language-independent assessment deployable by trained staff across multi-site studies.
Measure intervention impact
Quantify cognitive change as a direct outcome of pharmacological, behavioral, or device-based interventions, with sensitivity to within-subject change over time.
Two products.One core technology.Each designed for specific clinical pharmaceutical research.
Selecting the right product for your study
Both products share the same core technology. The choice between them depends on the study design and the intended use of the data.
ViewMind Neuroscan™
A 10-minute brain health assessment used in studies of cognitive optimization, lifestyle interventions, and pre/post measurement of clinical or wellness protocols.
ViewMind Atlas™
Designed for clinical and research-grade applications, particularly studies focused on neurodegenerative conditions. Used in BioHermes-002 and other multi-center clinical studies.
Validated against gold-standard biological and clinical markers
ViewMind's validation spans:
- Biological biomarkers: PET amyloid/tau, plasma GFAP and YKL-40.
- Neuroimaging: retinal OCT, MRI volumetrics.
- Cognitive testing: 20+ standard neuropsychological assessments including RBANS and MoCA.
Published results show sensitivity to preclinical pathology, strong concordance with established clinical measures. Diagnostic accuracy up to AUC 0.88. Test-retest reliability is classified as Excellent (W ≈ 0.9).
Validated across neurological conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Frontotemporal Dementia (FTD)
Parkinson's disease (PD)Multiple Sclerosis (MS)
Long COVID · CADASIL
Validated across neuropsychiatric conditions
Major Depressive Disorder (MDD)Bipolar DisorderADHD
Research partnershipswith global leaders
BioHermes-002
ViewMind Atlas is included in BioHermes-002, validating novel biomarkers in patients at risk of or diagnosed with Alzheimer's disease.
1,000 patients across 32 clinical sites.